EP1605893A4 - Trans-membran-antikörper-induzierte apoptose-hemmung - Google Patents

Trans-membran-antikörper-induzierte apoptose-hemmung

Info

Publication number
EP1605893A4
EP1605893A4 EP04718110A EP04718110A EP1605893A4 EP 1605893 A4 EP1605893 A4 EP 1605893A4 EP 04718110 A EP04718110 A EP 04718110A EP 04718110 A EP04718110 A EP 04718110A EP 1605893 A4 EP1605893 A4 EP 1605893A4
Authority
EP
European Patent Office
Prior art keywords
apoptosis
trans
membrane
induced inhibition
antibody induced
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP04718110A
Other languages
English (en)
French (fr)
Other versions
EP1605893A2 (de
Inventor
Heinz Kohler
Sybille Muller
Thomas L Brown
Yunfeng Zhao
Alton C Morgan Jr
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Innexus Biotechnology Inc Canada
Immpheron Inc
Original Assignee
Innexus Biotechnology Inc Canada
Immpheron Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Innexus Biotechnology Inc Canada, Immpheron Inc filed Critical Innexus Biotechnology Inc Canada
Publication of EP1605893A2 publication Critical patent/EP1605893A2/de
Publication of EP1605893A4 publication Critical patent/EP1605893A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4208—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
    • C07K16/4241—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig
    • C07K16/4258—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig against anti-receptor Ig
    • C07K16/4266—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig against anti-receptor Ig against anti-tumor receptor Ig
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Communicable Diseases (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
EP04718110A 2003-03-05 2004-03-05 Trans-membran-antikörper-induzierte apoptose-hemmung Withdrawn EP1605893A4 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US45198003P 2003-03-05 2003-03-05
US451980P 2003-03-05
PCT/US2004/006911 WO2004078146A2 (en) 2003-03-05 2004-03-05 Trans-membrane-antibody induced inhibition of apoptosis

Publications (2)

Publication Number Publication Date
EP1605893A2 EP1605893A2 (de) 2005-12-21
EP1605893A4 true EP1605893A4 (de) 2008-08-13

Family

ID=32962675

Family Applications (1)

Application Number Title Priority Date Filing Date
EP04718110A Withdrawn EP1605893A4 (de) 2003-03-05 2004-03-05 Trans-membran-antikörper-induzierte apoptose-hemmung

Country Status (5)

Country Link
EP (1) EP1605893A4 (de)
JP (1) JP2006522122A (de)
KR (1) KR20060006775A (de)
CA (1) CA2518119A1 (de)
WO (1) WO2004078146A2 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102004049479A1 (de) * 2004-10-11 2006-04-13 Scil Proteins Gmbh Proteinkonjugate zur Verwendung in Therapie, Diagnose und Chromatographie
CA2625951A1 (en) * 2005-09-01 2007-03-08 National Research Council Of Canada Anti-apoptotic protein antibodies
IT1392238B1 (it) * 2008-12-02 2012-02-22 Fond Santa Lucia Uso della caspasi-3 per la malattia dell'alzheimer
CA2758378A1 (en) * 2009-04-14 2010-10-21 Trojan Technologies Ltd. Therapeutic antennapedia-antibody molecules and methods of use thereof
EP2968546B1 (de) * 2013-03-15 2023-09-20 Omeros Corporation Verfahren zur erzeugung von bioaktivem peptid tragenden antikörpern und zusammensetzungen damit
US10456475B2 (en) 2015-02-03 2019-10-29 Kennsaw State University Research and Service Foundation, Inc. Cell penetrating protein adaptor molecules and their application in research and medicine
US10435446B2 (en) 2015-06-03 2019-10-08 Kennesaw State University Research and Service Foundation Inc. Cell penetrating protein adaptor molecules and their application in research and medicine
MA44334A (fr) 2015-10-29 2018-09-05 Novartis Ag Conjugués d'anticorps comprenant un agoniste du récepteur de type toll
US10654894B2 (en) 2016-02-03 2020-05-19 Keenesaw State University Research And Service Foundation, Inc. Methods for delivering cargo into a cell by using signal molecules as cell penetration agents

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001060866A1 (en) * 2000-02-15 2001-08-23 The Secretary Of State For Defence Anti-viral conjugate comprising a factor allowing the translocation of a protein across a cell membrane and comprising a single-chain antibody fragment directed against a viral protein
US6316003B1 (en) * 1989-12-21 2001-11-13 Whitehead Institute For Biomedical Research Tat-derived transport polypeptides
US20020143142A1 (en) * 1998-03-31 2002-10-03 Vanderbilt University Sequence and method for genetic engineering of proteins with cell membrane translocating activity
EP1488804A1 (de) * 2002-03-22 2004-12-22 Bipha Corporation Immunoglobulin/hydrophile peptidkomplexe

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2813630B2 (ja) * 1987-02-20 1998-10-22 ジェネンテク，インコーポレイテッド ヒト免疫不全ウイルスのエンベロープポリペプチドおよびその抗体
US5242824A (en) * 1988-12-22 1993-09-07 Oncogen Monoclonal antibody to human carcinomas
WO2001040276A2 (en) * 1999-12-06 2001-06-07 Agensys, Inc Serpentine transmembrane antigens expressed in human prostate cancers and uses thereof
AU2001293533A1 (en) * 2000-09-08 2002-03-22 Merck Frosst Canada & Co. Gamma-ketoacid dipeptides as inhibitors of caspase-3
JP2002355077A (ja) * 2001-02-23 2002-12-10 Takeda Chem Ind Ltd カスパーゼ３阻害剤

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6316003B1 (en) * 1989-12-21 2001-11-13 Whitehead Institute For Biomedical Research Tat-derived transport polypeptides
US20020143142A1 (en) * 1998-03-31 2002-10-03 Vanderbilt University Sequence and method for genetic engineering of proteins with cell membrane translocating activity
WO2001060866A1 (en) * 2000-02-15 2001-08-23 The Secretary Of State For Defence Anti-viral conjugate comprising a factor allowing the translocation of a protein across a cell membrane and comprising a single-chain antibody fragment directed against a viral protein
EP1488804A1 (de) * 2002-03-22 2004-12-22 Bipha Corporation Immunoglobulin/hydrophile peptidkomplexe

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
MULLER SYBILLE ET AL: "TransMabs: cell-penetrating antibodies, the next generation", EXPERT OPINION ON BIOLOGICAL THERAPY, ASHLEY, LONDON, GB, vol. 5, no. 2, 1 February 2005 (2005-02-01), pages 237 - 241, XP008093137, ISSN: 1471-2598 *
ROJAS M ET AL: "GENETIC ENGINEERING OF PROTEINS WITH CELL MEMBRANE PERMEABILITY", NATURE BIOTECHNOLOGY, NATURE PUBLISHING GROUP, NEW YORK, NY, US, vol. 16, no. 4, 1 April 1998 (1998-04-01), pages 370 - 375, XP001118371, ISSN: 1087-0156 *
STEIN S ET AL: "A disulfide conjugate between anti-tetanus antibodies and HIV (37-72)Tat neutralizes tetanus toxin inside chromaffin cells", FEBS LETTERS, ELSEVIER, AMSTERDAM, NL, vol. 458, no. 3, 24 September 1999 (1999-09-24), pages 383 - 386, XP004260296, ISSN: 0014-5793 *
ZHAO Y ET AL: "MTS-conjugated-antiactive caspase 3 antibodies inhibit actinomycin D-induced apoptosis.", APOPTOSIS : AN INTERNATIONAL JOURNAL ON PROGRAMMED CELL DEATH DEC 2003, vol. 8, no. 6, December 2003 (2003-12-01), pages 631 - 637, XP002485667, ISSN: 1360-8185 *

Also Published As

Publication number Publication date
JP2006522122A (ja) 2006-09-28
CA2518119A1 (en) 2004-09-16
EP1605893A2 (de) 2005-12-21
KR20060006775A (ko) 2006-01-19
WO2004078146A2 (en) 2004-09-16
WO2004078146A3 (en) 2006-01-05

Similar Documents

Publication Publication Date Title
GB0403041D0 (en) Induction of apoptosis
HK1096972A1 (en) Inhibition of syk kinase expression
GB2424887B (en) Sequence-specific inhibition of small RNA function
ZA200605348B (en) Solid forms of anti-EGFR-antibodies
EP1537102A4 (de) Inhibitoren von phosphoinositid-3-kinase beta
HK1077762A1 (zh) TFGß[轉化生長因子]的抑制劑
LT1610784T (lt) 5-azacitidino formos
IL165475A0 (en) Nitrooxyderivatives of eyclooxygenase-2 inhibitors
EP1771203A4 (de) Inhibition von nf-kb
EP1605893A4 (de) Trans-membran-antikörper-induzierte apoptose-hemmung
GB0424768D0 (en) Inhibition of clay or shale
AU2003234190A8 (en) Inhibition of immune complex formation
EP1658274A4 (de) Inhibitoren von cathepsin s
EP1613268A4 (de) Verfahren zur hemmung der angiogenese
AU2003299137A8 (en) Inhibition of metallo-beta-lactamase
EP1613736A4 (de) Hemmung der viruspathogenese
EP1627064A4 (de) Hemmung der blüte
DE60307471D1 (de) Hemmung
GB0227886D0 (en) Prion inhibition
GB0313644D0 (en) Inhibition of infection
GB0318913D0 (en) Apoptosis inhibitors
EP1677782A4 (de) Inhibitoren von cathepsin s
AU152108S (en) Set of pavers
GB0310268D0 (en) Inhibition of biofilm formation
GB0404518D0 (en) Protection of sanitaryware

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20051004

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK

PUAK Availability of information related to the publication of the international search report

Free format text: ORIGINAL CODE: 0009015

RIC1 Information provided on ipc code assigned before grant

Ipc: G01N 33/554 20060101ALI20060202BHEP

Ipc: G01N 33/541 20060101ALI20060202BHEP

Ipc: G01N 33/533 20060101ALI20060202BHEP

Ipc: A61K 51/10 20060101ALI20060202BHEP

Ipc: A61K 39/44 20060101ALI20060202BHEP

Ipc: A61K 39/395 20060101ALI20060202BHEP

Ipc: C07K 16/28 20060101ALI20060202BHEP

Ipc: C07K 16/00 20060101AFI20060202BHEP

DAX Request for extension of the european patent (deleted)
RIN1 Information on inventor provided before grant (corrected)

Inventor name: MORGAN, ALTON C., JR.,INNEXUS BIOTECHNOLOGY, INC.

Inventor name: ZHAO, YUNFENG,C/O LSU HEALTH SCIENCE CENTER

Inventor name: BROWN, THOMAS, L.

Inventor name: MULLER, SYBILLE

Inventor name: KOHLER, HEINZ

A4 Supplementary search report drawn up and despatched

Effective date: 20080710

17Q First examination report despatched

Effective date: 20081223

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20090703